Prescription

AI Stocks Targeting Opportunities in the Global Healthcare Market

Retrieved on: 
Wednesday, April 10, 2024
Crypto, Depression, Mining, Algorithm, Health, Metropolis, Patient, Social media, Artificial intelligence, History, Sale, LLM, USD, Marketing, Risk, Policy, Chemistry, Renewable energy, OTCQB, Conditional sentence, Organization, Sport, Drug discovery, Hospital, Research, Unified, Publishing, News, Acquisition, Prescription, AI, Robotics, Dell Technologies, Drug development, API, Diagnosis, Pressure, Environment, Disclosure, Biology, Dell, NVIDIA, Medicine, Medical device

The AI in Healthcare market is projected to grow from USD 20.9 billion in 2024 and reach USD 148.4 billion by 2029.

Key Points: 
  • The AI in Healthcare market is projected to grow from USD 20.9 billion in 2024 and reach USD 148.4 billion by 2029.
  • Betting on healthcare as a key market, Avant Technologies, Inc. (OTCQB: AVAI) just announced the completion of its acquisition of privately-held healthcare technology and data integration services firm, Wired-4-Health.
  • "By helping healthcare companies easily build and manage AI solutions, we're enabling them to harness the full power and potential of generative AI."
  • For investors following AI stocks, the hunt is on for finding the stocks that can harness the power of AI for the next generation of healthcare.

Food & Society at the Aspen Institute Releases the 2024 Food is Medicine Research Action Plan

Retrieved on: 
Tuesday, April 9, 2024
Emory University, Organization, Conference, Walmart, Policy, Associated, Health equity, Diabetes, Senior lecturer, Aspen, Research, Prescription, Doctor of Philosophy, Quality of life, White House conference, Society, Nutrition, University of Massachusetts, Aspen Institute, Physician, Meal, Dietary supplement

Washington, DC, April 09, 2024 (GLOBE NEWSWIRE) -- Food & Society at the Aspen Institute has released its 2024 Food is Medicine Research Action Plan.

Key Points: 
  • Washington, DC, April 09, 2024 (GLOBE NEWSWIRE) -- Food & Society at the Aspen Institute has released its 2024 Food is Medicine Research Action Plan.
  • It is the first report to pull together the latest peer-reviewed Food is Medicine research in a digestible, comprehensible, and action-oriented format.
  • Associated health outcomes like diabetes and heart disease remain far greater among Black and Latinx individuals and households.
  • Like the original, the revised version of the Research Action Plan has been made possible thanks to the continuing support of the Walmart Foundation.

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Biopsy, Fatty liver disease, Cirrhosis, Exercise, F2, Patient, Prescription, MD, Diet, Fibrosis, Pharmacy, NASH, Therapy, FDA, THR, JD

I can finally tell my appropriate patients with moderate to advanced fibrosis that we have an approved treatment to help improve fibrosis and resolve NASH.

Key Points: 
  • I can finally tell my appropriate patients with moderate to advanced fibrosis that we have an approved treatment to help improve fibrosis and resolve NASH.
  • Madrigal is committed to helping appropriate patients who may benefit from Rezdiffra access the medication through the Madrigal Patient Support program.
  • This program is designed to help patients navigate insurance and affordability challenges and provide co-pay support for eligible patients.
  • Madrigal has also established a patient assistance program (PAP) to help patients with no insurance access Rezdiffra.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Monday, April 8, 2024
Prior, Apoptosis, ALS, District court, Patient, AMX0035, Amyotrophy, Ext, LLP, Prescription, IBD, Complaint, Pomerantz, Action Replay, Food, Court, Evercore, Person, Pharmaceutical industry

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Wednesday, April 3, 2024
Patient, LLP, Prescription, IBD, Investor's Business Daily, Amylyx Pharmaceuticals, Advertising, Court, BBC World Service, Evercore, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Capsa Healthcare Unveils Enhanced KL1Plus Pharmacy Automation with New Aura Platform

Retrieved on: 
Tuesday, April 2, 2024
Program management, OTA, Pharmacy, Pharmacist, Prescription, Safety

COLUMBUS, Ohio, April 02, 2024 (GLOBE NEWSWIRE) -- Capsa Healthcare, a global leader in advanced healthcare workflow solutions, announces the enhanced KL1Plus pharmacy prescription filling device, now powered by Capsa’s innovative Aura platform.

Key Points: 
  • COLUMBUS, Ohio, April 02, 2024 (GLOBE NEWSWIRE) -- Capsa Healthcare, a global leader in advanced healthcare workflow solutions, announces the enhanced KL1Plus pharmacy prescription filling device, now powered by Capsa’s innovative Aura platform.
  • Pablo Arias, Director of Program Management at Capsa Healthcare, emphasizes the significance of the Aura platform in driving product design excellence.
  • The updated KL1Plus, featuring the Aura platform, significantly improves the working experience for pharmacists and pharmacy technicians.
  • For more information about Capsa Healthcare and the KL1Plus with Aura, visit the KL1Plus information page .

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, April 1, 2024
Commitment, Research, Obesity, PTE, Exercise, Bariatrics, Patent, Patient, Food and Drug Administration, Weight loss, Travel, Acquisition, FLEX, Prescription, NYU, Food, Security (finance), Insurance, Marketing, Surgeon, C-peptide, Annual report, PMA, NYU Langone Health, Division, United States patent law, FDA, Advertising, Bariatric surgery

IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate strategic update.

Key Points: 
  • Specifically, it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 18/370,819.
  • December 2023: Engaged Maxim Group LLC, to act as the company’s exclusive financial advisor to help identify potential synergistic merger and acquisition partnerships.
  • December 2023: Received U.S. Food and Drug Administration (FDA) PMA supplement approval for its next-generation Lap-Band® 2.0 FLEX, designed to improve the patient experience.
  • Participants using this feature are requested to dial into the conference call fifteen minutes ahead of time to avoid delays.

AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc.

Retrieved on: 
Monday, April 1, 2024
Apoptosis, ALS, District court, Patient, AMX0035, News, Prescription, Complaint, Action Replay, Amylyx Pharmaceuticals, Food, Court, Advertising, Pharmaceutical industry

If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.

Key Points: 
  • If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 9, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Sunday, March 31, 2024
Prior, Apoptosis, ALS, District court, Patient, AMX0035, Amyotrophy, Ext, LLP, Prescription, IBD, Complaint, Pomerantz, Action Replay, Food, Court, Evercore, Person, Pharmaceutical industry

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NYCB, Amylyx, Xponential, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 30, 2024
SSS, Signature, Vii, Apoptosis, ALS, Patient, AUV, Bloomberg Businessweek, ACL, Food and Drug Administration, Defendant, AMX0035, Amyotrophy, Sale, News, Dermatology, Prescription, New York Community Bank, NYCB, IBD, Complaint, P.C, Geisler, Investor's Business Daily, Assumption, Confidentiality, Amylyx Pharmaceuticals, Injury, Category, Dentist, FDA, BBC World Service, Evercore, Food, Pharmaceutical industry

NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.

Key Points: 
  • NYCB is a large commercial-real estate lender in the New York City market area, where it specializes in rent-regulated, non-luxury apartment buildings.
  • NYCB is engaged in several national businesses, including multi-family lending, mortgage originations and servicing, and warehouse lending.
  • On January 31, 2024, before the market opened, NYCB announced its fiscal fourth quarter 2023 financial results.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD